Literature DB >> 33387032

Does the administration of meloxicam before head and neck radiotherapy reduce the risk of mandibular osteoradionecrosis? An animal model study.

Mayra Cristina Yamasaki1, Gina Delia Roque-Torres2, Leonardo Vieira Peroni2, Eduarda Helena Leandro Nascimento2, Benjamin Salmon3,4, Matheus Lima Oliveira2, Deborah Queiroz Freitas2, Lourenço Correr-Sobrinho5.   

Abstract

OBJECTIVE: To assess whether the administration of meloxicam before head and neck radiotherapy reduces the risk of mandibular osteoradionecrosis in rats.
MATERIAL AND METHODS: Sixty male Wistar rats were randomly divided into 6 groups (n = 10) according to the meloxicam administration and radiation therapy: control (C), irradiated (I), single dose of meloxicam (M1), single dose of meloxicam and irradiated (M1I), triple dose of meloxicam (M3), triple dose of meloxicam and irradiated (M3I). Meloxicam was administrated (20 mg/kg per dose) 1 h before the radiation therapy (single dose of 20 Gy) and 24 h and 48 h after the radiation therapy for groups with two additional doses. Ten days after the radiation therapy, the three right mandibular molars were extracted from all rats, who were euthanatized after 21 or 35 days (n = 5 per group). The mandibles were assessed by macroscopic evaluation and micro-CT analysis.
RESULTS: The right hemimandibles of the irradiated groups revealed macroscopic signs of osteoradionecrosis, and those of the non-irradiated groups revealed complete gingival healing. A significant delay in alveolar socket healing in all irradiated groups was observed in the micro-CT assessment regardless meloxicam treatment.
CONCLUSION: The administration of meloxicam before head and neck radiotherapy does not reduce the risk of mandibular osteoradionecrosis when associated to dental extractions. CLINICAL RELEVANCE: Since meloxicam has been shown to be a potential radiation-protective agent, and osteoradionecrosis physiopathology is believed to be related to an inflammatory process, possible interactions are relevant to be investigated.

Entities:  

Keywords:  Animal experimentation; Non-steroidal anti-inflammatory agents; Osteoradionecrosis; Radiation-protective agents; Radiotherapy; X-ray microtomography

Year:  2021        PMID: 33387032     DOI: 10.1007/s00784-020-03701-x

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  23 in total

1.  A single dose of an inhibitor of cyclooxygenase 2, meloxicam, administered shortly after irradiation increases survival of lethally irradiated mice.

Authors:  M Hofer; M Pospíšil; L Dušek; Z Hoferová; L Weiterová
Journal:  Radiat Res       Date:  2011-06-10       Impact factor: 2.841

Review 2.  Contemporary radiotherapy in head and neck cancer: balancing chance for cure with risk for complication.

Authors:  Alvin R Cabrera; David S Yoo; David M Brizel
Journal:  Surg Oncol Clin N Am       Date:  2013-03-14       Impact factor: 3.495

Review 3.  COX-2 in Radiotherapy: A Potential Target for Radioprotection and Radiosensitization.

Authors:  Mohsen Cheki; Rasoul Yahyapour; Bagher Farhood; Abolhassan Rezaeyan; Dheyauldeen Shabeeb; Peyman Amini; Saeed Rezapoor; Masoud Najafi
Journal:  Curr Mol Pharmacol       Date:  2018       Impact factor: 3.339

4.  Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A₃ receptor agonist on hematopoiesis in sublethally γ-irradiated mice.

Authors:  Michal Hofer; Milan Pospíšil; Ladislav Dušek; Zuzana Hoferová; Lenka Weiterová
Journal:  Biomed Pharmacother       Date:  2011-06-12       Impact factor: 6.529

5.  Meloxicam, a cyclooxygenase 2 inhibitor, supports hematopoietic recovery in gamma-irradiated mice.

Authors:  M Hofer; M Pospísil; V Znojil; J Holá; A Vacek; L Weiterová; D Streitová; A Kozubík
Journal:  Radiat Res       Date:  2006-09       Impact factor: 2.841

6.  Inhibition of cyclooxygenase 2 in mice increases production of g-csf and induces radioprotection.

Authors:  M Hofer; M Pospísil; J Holá; A Vacek; D Streitová; V Znojil
Journal:  Radiat Res       Date:  2008-11       Impact factor: 2.841

7.  Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.

Authors:  Seong-Hee Ko; Geun Jun Choi; Ji Hye Lee; Yoon A Han; Soo-Jeong Lim; So Hee Kim
Journal:  Oncol Rep       Date:  2008-02       Impact factor: 3.906

Review 8.  Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer.

Authors:  Derrick T Lin; Kotha Subbaramaiah; Jatin P Shah; Andrew J Dannenberg; Jay O Boyle
Journal:  Head Neck       Date:  2002-08       Impact factor: 3.147

9.  COX-2 inhibitors are contraindicated for treatment of combined injury.

Authors:  W Jiao; J G Kiang; L Cary; T B Elliott; T C Pellmar; G D Ledney
Journal:  Radiat Res       Date:  2009-12       Impact factor: 2.841

10.  Recovery from hematopoietic injury by modulating prostaglandin E(2) signaling post-irradiation.

Authors:  Jonathan Hoggatt; Pratibha Singh; Kayla N Stilger; P Artur Plett; Carol H Sampson; Hui Lin Chua; Christie M Orschell; Louis M Pelus
Journal:  Blood Cells Mol Dis       Date:  2012-11-30       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.